Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).
Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.
Rebeiz
Abdallah G
AG
Duke Clinical Research Institute, Durham, North Carolina, USA.
Dery
Jean-Pierre
JP
Tsiatis
Anastasios A
AA
O'shea
J Conor
JC
Johnson
Brent A
BA
Hellkamp
Anne S
AS
Pieper
Karen S
KS
Gilchrist
Ian C
IC
Slater
James
J
Muhlestein
J Brent
JB
Joseph
Diane
D
Kitt
Michael M
MM
Tcheng
James E
JE
D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D003327:Coronary Disease / Q000628:therapy*; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form; D004311:Double-Blind Method; D000077542:Eptifibatide; D006801:Humans; D007261:Infusions, Intra-Arterial; D007527:Isoenzymes / Q000097:blood; D009203:Myocardial Infarction / Q000097:blood / Q000209:etiology / Q000401:mortality; D009656:North America / Q000453:epidemiology; D010455:Peptides / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011183:Postoperative Complications / Q000097:blood / Q000209:etiology / Q000401:mortality; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D007527:Isoenzymes; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D000077542:Eptifibatide